Treatment slows onset of Alzheimer’s

Israel’s Avraham Pharmaceuticals announced successful interim results in a Phase 2b clinical trial of ladostigil, for the treatment of mild cognitive impairment (MCI). Fewer MCI patients using ladostigil for 2 years progressed to Alzheimer’s than those using the placebo.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *